Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ORAGENICS INCOGEN · Entity 8495 | CEO and CFO | December 11, 2025 | December 15, 2025 |
| Scienture Holdings, Inc.MEDS · Entity 7802 | CFO, PAO, PFO | December 13, 2022 | February 24, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ORAGENICS INC
Report date December 11, 2025 · Filed December 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2035-12-11 | Direct | 250,000 |
Reported balance
After 2025-12-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-11 · Grant · Acquired 250,000 · Balance 250,000 F1: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. One third of the options vest on the first anniversary of the grant date and the remainder of the options subsequently vest in equal annual installments over the second and third anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the Company's closing price on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. One third of the options vest on the first anniversary of the grant date and the remainder of the options subsequently vest in equal annual installments over the second and third anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the Company's closing price on the date of grant.
Scienture Holdings, Inc.
Report date December 13, 2022 · Filed February 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 71,551 |
Reported balance
After 2022-12-13 transaction · row 1
1 source rowRow 1 · 2022-12-13 · Grant · Acquired 50,000 · Balance 71,551 F1: Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on December 31, 2022, March 31, 2023, June 30, 2023 and September 30, 2023, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d). F2: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as Chief Financial Officer. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on December 31, 2022, March 31, 2023, June 30, 2023 and September 30, 2023, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d).
F2: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as Chief Financial Officer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2025 Filed Dec 15, 2025 21:55 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001866284-25-000002 · primary_doc.xml · derivative · entry 1 Huffman Janet · CIK 0001866284 · CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2035-12-11 F1 · security: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. One third of the options vest on the first anniversary of the grant date and the remainder of the options subsequently vest in equal annual installments over the second and third anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the Company's closing price on the date of grant. F1 · shares: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. One third of the options vest on the first anniversary of the grant date and the remainder of the options subsequently vest in equal annual installments over the second and third anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the Company's closing price on the date of grant. F1 · derivative.exercise_date: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. One third of the options vest on the first anniversary of the grant date and the remainder of the options subsequently vest in equal annual installments over the second and third anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the Company's closing price on the date of grant. F1 · balance_after: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. One third of the options vest on the first anniversary of the grant date and the remainder of the options subsequently vest in equal annual installments over the second and third anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the Company's closing price on the date of grant. Read SEC document |
| September 19, 2024 Filed Sep 21, 2024 01:15 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantEmployee Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001493152-24-037730 · ownership.xml · derivative · entry 1 Huffman Janet · CIK 0001866284 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2034-09-19 F1 · security: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. The option shares vest immediately. The option exercise price is the Company's closing price on the date of grant. F1 · shares: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. The option shares vest immediately. The option exercise price is the Company's closing price on the date of grant. F1 · derivative.exercise_date: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. The option shares vest immediately. The option exercise price is the Company's closing price on the date of grant. F1 · balance_after: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. The option shares vest immediately. The option exercise price is the Company's closing price on the date of grant. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 20:30 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-027578 · ownership.xml · nonDerivative · entry 1 Huffman Janet · CIK 0001866284 · CFO, Secretary and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents an award of restricted stock of the Company's common stock under the Company's 2021 Equity Incentive Plan in connection with serving as the Company Secretary, Treasurer and Chief Financial Officer with 10,000 shares vesting immediately and 5,000 shares vesting in six (6) months. Read SEC document |
| March 07, 2023 Filed Mar 8, 2023 21:31 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantEmployee Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001493152-23-007010 · ownership.xml · derivative · entry 1 Huffman Janet · CIK 0001866284 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2033-03-07 F1 · shares: Represents an award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan in connection with the engagement to serve as the Company's Chief Financial Officer. The options vest as follows: 1,400 options vest on the grant date, 1,400 options vest on September 7, 2023, 1,400 options vest on March 7, 2024, 1,400 options vest on September 7, 2024, and 1,400 options vest on March 7, 2025. The option exercise price is the Company's closing price on the date of grant. F1 · balance_after: Represents an award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan in connection with the engagement to serve as the Company's Chief Financial Officer. The options vest as follows: 1,400 options vest on the grant date, 1,400 options vest on September 7, 2023, 1,400 options vest on March 7, 2024, 1,400 options vest on September 7, 2024, and 1,400 options vest on March 7, 2025. The option exercise price is the Company's closing price on the date of grant. Read SEC document |
| December 13, 2022 Filed Feb 24, 2023 16:45 UTC | Scienture Holdings, Inc. MEDS · Entity 7802 | GrantCommon stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-006014 · ownership.xml · nonDerivative · entry 1 Huffman Janet · CIK 0001866284 · CFO, PAO, PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,551 F1 · shares: Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on December 31, 2022, March 31, 2023, June 30, 2023 and September 30, 2023, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d). F2 · price: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as Chief Financial Officer. Read SEC document |
| September 01, 2022 Filed Sep 16, 2022 17:17 UTC | Scienture Holdings, Inc. MEDS · Entity 7802 | GrantCommon stock | 21,551 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-026112 · ownership.xml · nonDerivative · entry 1 Huffman Janet · CIK 0001866284 · CFO, PAO, PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,551 F1 · shares: Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on September 30, 2022, October 31, 2022, November 30, 2022 and December 31, 2022, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d). F2 · price: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as Chief Financial Officer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.